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Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable
disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most
patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004
and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV)
and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will
continue to rise with new treatments including sofosbuvir, which now include interferon
free regimens.
de Bruijn et al. HCV Medicines
Objective: Assess the uptake of BCV and TVR across Europe from a health authority
perspective to offer future guidance on dealing with new high cost medicines.
Methods: Cross-sectional descriptive study of medicines to treat HCV (pegIFN, ribavirin,
BCV and TVR) among European countries from 2008 to 2013. Utilization measured in
defined daily doses (DDDs)/1000 patients/quarter (DIQs) and expenditure in Euros/DDD.
Health authority activities to influence treatments categorized using the 4E methodology
(Education, Engineering, Economics and Enforcement).
Results: Similar uptake of BCV and TVR among European countries and regions,
ranging from 0.5 DIQ in Denmark, Netherlands and Slovenia to 1.5 DIQ in Tayside and
Catalonia in 2013. However, different utilization of the new PIs vs. ribavirin indicates
differences in dual vs. triple therapy, which is down to factors including physician
preference and genotypes. Reimbursed prices for BCV and TVRwere comparable across
countries.
Conclusion: There was reasonable consistency in the utilization of BCV and TVR among
European countries in comparison with other high priced medicines. This may reflect the
social demand to limit the transmission of HCV. However, the situation is changing with
new curative medicines for HCV genotype 1 (GT1) with potentially an appreciable budget
impact. These concerns have resulted in different prices across countries, with their
impact on budgets and patient outcomes monitored in the future to provide additional
guidance.
Keywords: boceprevir, cross national drug utilization study, demand-side measures, Hepatitis C, introduction new
medicines, sofosbuvir, telaprevir
INTRODUCTION
The incidence and prevalence of patients with hepatitis C
virus (HCV) infection is growing. However, the true worldwide
incidence remains unknown due to heterogeneous registration
and case definitions (European Centre for Desease Prevention
Control, 2010). Overall, it is believed that the diagnosed global
prevalence of HCV is approximately 2.0% (1.7–2.3%) for adults,
which corresponds to approximately 104 (87–124) million
persons world-wide (Table 1; McGowan et al., 2013; Mohd
Hanafiah et al., 2013; European Association for the Study of the
Liver, 2014; Hope et al., 2014; Wedemeyer et al., 2015). Others
have suggested higher figures at 2.8% globally (Lemoine and
Asia, 2014), leading to estimated prevalence rates of 150–184
million world-wide (Ramachandran et al., 2012; Mohd Hanafiah
et al., 2013; Lemoine and Asia, 2014; Phelan and Cook, 2014;
Barua et al., 2015; Cure et al., 2015; Norton, 2015; Fraser et al.,
2016), with approximately 85% of patients living in low to middle
income (LMIC) countries (Phelan and Cook, 2014). However,
estimated figures for South Africa are lower at 0.1–1.7% (Fraser
et al., 2016). In 2013, diagnosis rates vs. the estimated prevalence
rates varied from 81% in Sweden and 43% in Belgium to just
16% in Turkey (Table 1; Dore et al., 2014; Wedemeyer et al.,
2015).
Annually up to 0.5 million people die from the consequences
of chronic hepatitis C infection, mainly in Africa, Asia and
Eastern Europe (Lozano et al., 2012). Most people are unaware
of their HCV infection due to the slow progress of the disease
(Yehia et al., 2014), with sequelae of chronic hepatitis potentially
appearing up to 20–30 years later. These include liver cirrhosis,
which occurs in 10–20% of patients with hepatitis C, and
develops into a 1–5% annual risk of hepatocellular carcinoma and
3–6% annual risk of hepatic decompensation (Thein et al., 2008;
Westbrook and Dusheiko, 2014). In 2012, cirrhosis of the liver
was the tenth leading cause of death in LMIC countries (globally
the twelfth leading cause), with liver cancer the ninth leading
cause of death in upper-middle-income countries (globally the
sixteenth leading cause) (World Health Organisation, 2012;
Lemoine and Asia, 2014).
Until 2011, treatment choices and their effectiveness were
limited, especially for patients with genotype 1 (GT1). GT1HCV-
patients account for up to 60% of HCV infections worldwide, and
predominate in Eastern, Northern and Southern Europe as well
as North America and Japan (Schalm et al., 1997; McHutchison
et al., 1998; Poynard et al., 1998; Cebolla and Björnberg, 2012;
Messina et al., 2014). Cure rates, defined as sustained virological
response (SVR), were typically only seen in 35–43% of patients
with GT1 following dual therapy with ribavirin and pegylated
interferons (pegIFNs) (Schalm et al., 1997; McHutchison et al.,
1998; Poynard et al., 1998; Manns et al., 2013; Mathurin, 2013;
Chou et al., 2014; Kohli et al., 2014). However, the serious side-
effects associated with these treatments, coupled with complex
regimens, resulted in problems with adherence. This led to less
than 50% of patients typically completing their treatment course
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TABLE 1 | Reported anti-HCV prevalence rates (adjusted for the adult population), genotype 1 (GT1) distribution and estimated diagnose and treatment
rate (Dore et al., 2014; Gower et al., 2014; Hope et al., 2014; Wedemeyer et al., 2015).
AU BE DK EE ES FR HR IT NL SE TR UK
Adult anti-HCV 0.5% 0.9% 0.7% – 1.7% 0.6% – 2.0% 0.2% 0.7% 1.0% 0.6%
prevalence (0.1–0.7%) (0.1–1.2%) (0.5–0.7%) (0.4–2.6%) (0.4–1.1%) (1.6–7.3%) (0.1–0.4%) (0.5–0.7%) (0.6–2.1%) (0.4–1.2%)
Genotype 1a 20.3% – 34.0% 1.0% 25.5% 14.8% 13.1% 4.2% 14.8% 38.2% 8.1% 24.4%
Genotype 1b 51.6% 50.4% 12.0% 71.0% 43.8% 29.7% 37.4% 57.5% 15.7% 7.0% 83.7% 11.9%
Genotype 1c – 8.6% – – – – – – – – – –
Estimated diagnosed
rate (2013)
37% 43% 59% – 40% 69% – – 61% 81% 16% 35%
NB: AU, Austria; BE, Belgium; DK, Denmark; EE, Estonia; ES, Spain; FR, France; HR, Croatia; IT, Italy; NL, the Netherlands; SE, Sweden; TR, Turkey; UK, United Kingdom.
(McHutchison et al., 2002; Lo Re et al., 2011; Brennan and
Shrank, 2014).
In 2011, the direct acting antivirals (DAAs) boceprevir
(BCV), and telaprevir (TVR) became available (Chou et al.,
2014)1,2. BCV and TVR are only licensed for GT1. Consequently
physicians need to test for genotypes before starting treatment1,2.
BCV and TVR improved SVR (RR, 2.05; 95% CI 1.70–2.48) when
combined with ribavirin and pegIFNs (triple therapy) (Chou
et al., 2014; Kohli et al., 2014; Manzano-Robleda et al., 2015)3;
however, there were more adverse events (RR, 1.05; 1–1.03; NNH
77.59) (Manzano-Robleda et al., 2015). In recent years, second
generation DAAs have become available with encouraging cure
rates up to 90–95% of patients, potentially providing shorter
treatment courses and less side effects than previous treatment
approaches (Kohli et al., 2014; Childs-Kean and Hand, 2015)3.
These were sofosbuvir, simeprevir, daclatasvir and ledipasvir
approved by the European Medicine Agency (EMA) in late 2013
and 20144,5,6,7. More recently, combinations of DAAs have also
been approved by EMA providing further options for highly
1European Medicine Agency. Incivo - telaprevir [Internet]. [cited 18 Nov
2015] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/
medicines/human/medicines/002313/human_med_001487.jsp&mid=WC0b01ac
058001d124
2European Medicine Agency. Victrelis - boceprevir [Internet]. [cited 18 Nov
2015] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/
medicines/human/medicines/002332/human_med_001464.jsp&mid=WC0b01ac
058001d124
3California Technology Assessment Forum. The Comparative Clinical
Effectiveness and the Value of Simeprevir and Sofosbuvir in the Treatment of
Chronic Hepatitis C Infection: Final Report. San Francisco: California Technology
Assessment Forum; April 15, 2014. Available at URL: http://icer-review.org/wp-
content/uploads/2016/02/CTAF_Hep_C_Apr14_final.pdf (Accessed 8 July 2017).
4European Medicine Agency. EPAR Sovaldi sofosbuvir. [cited 2015 Nov]
Available at URL: http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Summary_for_the_public/human/002798/WC500160599.pdf
5European Medicine Agency. EPAR Olysio simeprevir. [cited 2015 Nov]
Available at URL: http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Summary_for_the_public/human/002777/WC500167869.pdf
6European Medicine Agency. EPAR daclatasvir. [Cited 2015
Nov]. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Public_assessment_report/human/003768/WC500172
849.pdf
7European Medicine Agency. EPAR Ledipasvir. Harvoni [Cited 2015 Nov].
Available from: http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Summary_for_the_public/human/003850/WC500177997.pdf
effective, safe and well tolerated treatment of HCV GT1 patients
(Kohli et al., 2014)8.
These developments resulted in the anti HCV therapeutics
market expanding at a compounded annual growth rate (CAGR)
of 2.7% between 2004 and 20119,10, with growth rates appreciably
higher after this10. This has resulted in worldwide sales of
sofosbuvir already at US$12.4 billion in 2014 (Trooskin et al.,
2015). In the US, treatments for hepatitis C became the fourth
most expensive speciality medicine class in 2014 with sofosbuvir
already capturing 37.5% of the HCV market11. These growth
rates in expenditure are due not only to the price of these new
treatments at over US$50,000/patient/course in some countries,
but also the effectiveness and limited side-effects of the second
generation DAAs (Mohd Hanafiah et al., 2013; Brennan and
Shrank, 2014; Senior, 2014). In addition, these new treatments
are being used in patients with advanced liver disease, such as
those with decompensated cirrhosis awaiting transplantation,
appreciably increasing the pool of eligible patients.
We are already seeing that some European health authorities
are unable to fund new high priced medicines, exacerbated by
their continual launch (Experts in Chronic Myeloid Leukemia,
2013; Kantarjian et al., 2013; Godman et al., 2015)12. This
will impact on available funding for new treatments for HCV
despite their undoubted effectiveness (Brennan and Shrank,
2014; Lemoine and Asia, 2014; Trooskin et al., 2015; Norton,
2015). The arrival of cost-effective second generation DAAs has
fuelled the debate over pricing and reimbursement decisions
8European Medicine Agency. EPAR ombitasvir/paritaprevir/ritonavir. [cited 2015
Oct] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Summary_for_the_public/human/003839/WC500184000.pdf
9Médecins Sans Frontières. THE DIAGNOSIS AND TREATMENT
OF HEPATITIS C?: A technical landscape. 2013. Available at URL:
http://www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/
HepC_brief_TechnicalLandscape_ENG_2013.pdf (Accessed 15 Oct 2015).
10Research and Markets. Hepatitis C Therapeutics Market to 2018 - Expected
Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free
Combination Therapy [Internet]. 2012. [cited 2015 Sept] Available from: http://
www.researchandmarkets.com/research/ngbvll/hepatitis_c
11Express Scripts. The 2014 Drug Trend Report. [cited 2015 Sept]. Available at
URL: http://lab.express-scripts.com/~/media/PDFs/Drug%20Trend%20Report/
ExpressScripts_DrugTrendReport.ashx (Last Accessed 8 July 2016).
12EFPIA. HEALTH and GROWTH - Evidence Compendium. October 30th, 2013.
Available from URL: http://www.efpia.eu/uploads/Modules/Documents/health-
and-growth_evidence-compendium.pdf
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across Europe given typically reimbursement for new expensive
cancer treatments and those for orphan diseases despite often
limited health gain, as well as whether there should be a greater
focus on the budget impact of new medicines rather than just
their cost-effectiveness (Kantarjian et al., 2013; Simoens et al.,
2013; Cohen and Felix, 2014; Godman et al., 2015; Messori,
2015a)13.
Consequently, the aim of this initial study is to compare the
uptake of BCV and TVR among European countries from a
health authority perspective alongside implemented activities to
influence their prescribing. We will subsequently build on the
findings, including current activities among health authorities
regarding second generation DAAs including price negotiations,
to provide future direction and guidance to health authorities
(Civaner, 2012; Lemoine and Asia, 2014)10. This will involve
specific studies to ascertain utilization and expenditure of second
generation DAAs alongside negotiated prices.
METHODS
This was a retrospective cross sectional descriptive observational
study involving twelve countries and regions from across Europe.
Health authorities were contacted to provide aggregated data on
the utilization and expenditure of BCV and TVR. This was purely
voluntary as there was no funding for them and no funding
to purchase utilization data from commercial sources. We have
used this approach before when analysing the influence of
different health authority measures to enhance the prescribing of
generic atypical antipsychotics, proton-pump inhibitors, renin-
angiotensin inhibitors, selective serotonin re-uptake inhibitors
and statins across Europe (Godman et al., 2010a, 2014a; Vonèina
et al., 2011; Moon et al., 2014).
The European countries and regions that provided utilization
and expenditure data typically cover 100% of their population.
However, there are differences in their geography, i.e., central,
eastern, and western European countries, epidemiology, and
financing of as well as available resources for healthcare (Table 2).
This is important given the heterogeneity of European healthcare
systems and suggested approaches when conducting cross
national studies (Cacace et al., 2013). The only exception to
health authority data is Turkey, where data from the Ministry of
Health were sourced from Intercontinental Marketing Services
(IMS).
The region of Catalonia is included as it is difficult to obtain
comprehensive drug utilization data from across Spain, and
Catalonia is one of the principal autonomous communities in
Spain, which has been active over a number of years with
initiatives to improve the quality and efficiency of prescribing
(Coma et al., 2009; Björkhem-Bergman et al., 2013). Tayside was
TABLE 2 | Details of methods of financing healthcare, GDP spent on health and data providers (Godman et al., 2010a, 2013a; Atun et al., 2013; Hesse
et al., 2013)14.
Country/ Taxation/ GDP/capita % GDP spent on Data providers (100% coverage of population
region health insurance (PPP in US $) health (2010–2014) unless otherwise stated)
Austria (AT) Health Insurance 43,390 11.0 Data Warehouse of the Federation of Austrian Social Insurance
Institutions—covers 98% of the population
Belgium (BE) Health Insurance 39,860 11.2 National Institute for Health and Disability Insurance (INAMI-RIZIV)
Croatia (HR) Health Insurance 18,760 7.3 Croatian Health Insurance Fund covering over 99% of the
population. HCV treatments funded from a separate budget for
expensive medicines
Denmark (DK) Taxation 43,430 10.6 Danish Prescription Registry
Estonia (EE) Health Insurance 22,500 5.7 Estonian Health Insurance Fund
France Health Insurance 38,847 11.8 SNIIRAM (The National Information System of public Health
Insurances)
Italy (IT) Taxation 32,920 9.1 Medicines Utilization Unit’s elaboration of data from Osmed
Database and Tracciabilità del farmaco
The Netherlands (NL) Health Insurance 43,510 12.9 The Drug Information System of Dutch National Health Care
Institute
Slovenia (SI) Health Insurance 27,240 9.2 The National Institute of Public Health and Health Insurance
Institute Prescription database
Spain—Catalonia (ES—CT) Taxation 31,670 8.9 Catalan Health Service drug prescription database (DATAMART)
Sweden (SE) Taxation 43,980 9.7 National Swedish Prescribed Drug Register
Turkey (TR) Health Insurance 18,020 5.6 Utilization information from the Ministry of Health sourced from IMS
UK—Scotland Taxation 37,340 9.1 Prescribing Information Systems (PIS) from NHS National Services
Scotland Corporate Warehouse
13WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Available at URL: http://
www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-
opportunities-for-collaboration-and-research.
14Health expenditure, total (% of GDP) - World Health Organization Global Health Expenditure database [Internet]. [cited 2015 Aug 17]. Available from:
http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS
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TABLE 3 | DDDs for medicines to treat Hepatitis C15.
Medicine ATC DDD
Bocepravir (BCV) J05AE11 2.4 g (oral)
Peg-interferon alfa-2a L03AB11 26 mcg (parenteral)
Peg-interferon alfa-2b L03AB10 7.5 mcg (parenteral)
Ribavirin J05AB04 1 gm (oral)
Telaprevir (TVR) J05AE11 2.25 gm (oral)
also included, representing a region in Scotland, since at the
time it was difficult to obtain drug utilization data from across
Scotland.
Utilization Data
Utilization data were collected in Defined Daily Doses (DDD)16,
with Table 3 providing details of the DDDs used.
Population data from Eurostat were used to calculate DDDs
per 1000 inhabitants per quarter (DIQs)17. Calculations were
performed using the quarterly time period since the treatment
period for HCV treatments is at least 12 weeks, and mostly 24 or
48 weeks, thereby providing a realistic denominator.
Results were calculated using two approaches. Firstly, the
utilization of BCV and TVRwas calculated separately to compare
their uptake across countries. Due to the lack of patient specific
data and different algorithms for BCV and TVR, their utilization
was not combined. The second approach was an estimation of
percentages of treated patients with triple therapy (ribavirin +
pegIFN + TVR + BCV) vs. dual-therapy (ribavirin + pegIFN).
This was again because we did not have access to individual
patient data nor to prevalence rates. The percentage of treated
patients was estimated through assessing the utilization of BCV
and TVR in relation to ribavirin. Ribavirin is used as a proxy for
dual-therapy because it is typically administered with pegIFNs,
although we are aware that some patients with GT3 may be
administered ribavirin without pegIFN. We acknowledge that
there are differences in GT1 prevalence rates among European
countries (Cornberg et al., 2011; Deuffic-Burban et al., 2012),
that treatment algorithm data are not always available and there
are different opinions and barriers to care (McGowan et al.,
2013). Differences in GT1 prevalence rates and current treatment
approaches are the most important uncertainties in this analysis.
Consequently, we made a number of caveats to give a more
realistic approach.
Estimates for GT1 is between 35 and 75% (Cornberg et al.,
2011; Deuffic-Burban et al., 2012) of patients with chronic HCV
(Table 1). In our approach, we used 45–65% to give a reasonable
perspective. TVR treatment length varies between 12 of 48 weeks
(25%) for patients with cirrhosis to 12 of 24 weeks (50%) for
15ATC/DDD Index 2013 [cited 2015 Sept]. Available from: http://www.whocc.no/
16World Health Organization (WHO). Introduction to Drug Utilization Research
World Health Organization WHO International Working Group for Drug
Statistics Methodology, Collaborating Centre for Drug Utilization Research and
Clinic. 2003. [cited 2015 Oct]. Available at URL: http://www.who.int/medicines/
areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf
17Eurostat. Population on 1 January. [cited 2015 Sept] Available from: http://epp.
eurostat.ec.europa.eu/tgm/table.do?tab=table&language=en&pcode=tps00001&
tableSelection=1&footnotes=yes&labeling=labels&plugin=1
TABLE 4 | Calculated percentages for triple therapy vs. all HCV treated
patients.
GT1 prevalence Treatment length Treatment length
for TVR between for BCV between
25 and 50% of full
treatment
67 and 92% of full
treatment
45% GT1 prevalence 11.3–22.5% 30.2–41.4%
65% GT1 prevalence 16.2–32.5% 43.5–59.7%
patients without cirrhosis and early SVR responses. For BCV,
treatment length varies between 32 of 48 (67%) weeks for some
treatment naïve patient without cirrhosis, mainly relapsers and
partial responders, and 44 of 48 (92%) weeks for patients with
cirrhosis (Christensen et al., 2012; Hofmann et al., 2012; Lagging
et al., 2012; Leroy et al., 2012; Orlent et al., 2012; Ramachandran
et al., 2012)1,2. Sixty five and forty five percent GT1 prevalence
rates were combined with percentages of treatment length, e.g.,
for TVR this was 25% use and 45% GT1 prevalence (25% of
45%) equating to 11.25%. Subsequently, the numbers used to
estimate the potential for triple therapy are between 11.3 and
32.5% utilization for TVR and 30.2 and 59.7% utilization for
BCV (Table 4). These findings define the second approach in
an attempt to estimate the number of patients receiving triple
therapy as a percentage of all HCV treated patients.
Reimbursement Expenditure Data
Reimbursement expenditure was calculated in Euros per DDD
(EUR/DDD). Exchange rates for Croatia, Denmark, Poland,
Sweden and Switzerland where pertinent were calculated using
the following conversion rates (conversion date 1-January 2008
as this was the start of the data collection period): 1 EUR =
7.6 HRK (Croatian Kuna), 7.46 DKK (Danish Krone), 9.44 SEK
(Swedish krona), 1.65 CHF (Swiss franc), and 3.60 PLN (Polish
zloty)18 .
Descriptive Review of National and
Regional Health Authority Demand-Side
Activities Regarding HCV Drug Treatment
for BCV and TVR
Measures undertaken by health authorities to potentially
influence the subsequent utilization of BCV and TVR were
collected and collated using the 4E—Education, Engineering,
Economics, and Enforcement (Wettermark et al., 2009)
methodology. This method was developed in order to make
it easier to understand and compare the complexity and
multiplicity of healthcare policies across countries and their
potential impact and/or influence (Coma et al., 2009;Wettermark
et al., 2009; Godman et al., 2010a,b; Godman et al., 2013b, 2014a;
Garuoliene et al., 2011; Vonèina et al., 2011; Malmström et al.,
2013). Table 5 shows definitions and gives some examples of the
four dimensions.
Country data were collected through an interactive and
iterative process. Answers to the developed questionnaire were
18Current andHistorical Rate Tables. [cited 2015 Sept] Available from: http://www.
xe.com/currencytables/?from=EUR&date=2008-01-01
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provided in written format by the co-authors, and subsequently
checked for accuracy. Alternatively, country profiles were
provided by one of the co-authors (Winnie De Bruijn) based
on published sources as well as web-based articles. As a result,
more European countries were included in the country profiles
of ongoing activities regarding BCV and TVR than provided
utilization data. Subsequent answers were re-checked and re-
confirmed with the co-authors to enhance the robustness of
the country profiles. This method has been used in previous
publications involving health authority personnel (Garuoliene
et al., 2010, 2011; Godman et al., 2010a,b, 2013b, 2014a,b;
Vonèina et al., 2011; Malmström et al., 2013); consequently,
applied in this research project.
All country profiles were supplemented with data from the
WHO Hepatitis report19 and Euro Hepatitis Index 2012 report
(Cebolla and Björnberg, 2012).
Patient consent as well as ethics approval was not required
as aggregate utilization and expenditure data were obtained
from anonymised health authority databases (Table 2). This is in
line with previous publications involving anonymised aggregated
health authority data Europe (Godman et al., 2010a, 2014a;
Vonèina et al., 2011; Moon et al., 2014).
RESULTS
General
In the majority of countries studied, both BCV and TVR were
reimbursed. Exceptions included Bosnia and Herzegovina as well
as Estonia (Table 6). Technically in Sweden only TVR is included
in the national reimbursement scheme. However, in practice,
19World Health Organization (WHO). Global policy report on the prevention
and control of viral hepatitis IN WHO MEMBER STATES. 2013. [cited
2015 Aug] Available at URL: http://apps.who.int/iris/bitstream/10665/85397/1/
9789241564632_eng.pdf?ua=1
both BCV and TVR are free for patients as both medicines are
free for infectious diseases under the Infectious Disease Act.
Activities among by Health Authorities to
Influence the Prescribing of BCV and TVR
Table 6 summarizes the variety of measures broken down by
the 4E method (Table 5) implemented by the various European
countries to improve themanagement of patients withHCV. This
includes any measures regarding subsequent utilization of BCV
and TVR.
All European countries studied had a national strategy
plan to manage patients with HCV, which typically included
prevention and control programmes and/or guidelines19. All
clinical guidelines available in English typically followed the strict
EMA recommendations, e.g., besides SVR monitoring, there
were also clear starting and stopping rules prior to initiating
treatment and continuing treatment (European Association for
the Study of the Liver, 2011; Hofmann et al., 2012; Lagging
et al., 2012; Leroy et al., 2012; Orlent et al., 2012; Ramachandran
et al., 2012)1,2. Where countries mostly differed was their opinion
regarding genotyping interleukin 28B (IL28B) polymorphism.
Some countries and regions recommend routine testing, e.g.,
Catalonia, whilst others currently do not test.
All countries studied had a surveillance system for either
acute and/or chronic HCV infections. Unfortunately current
registries are heterogeneous and differ mostly in case definition
(European Centre for Desease Prevention Control, 2010;
Cornberg et al., 2011; Yehia et al., 2014)20 . The EMA Committee
for Medicinal Products for Human Use (CHMP) emphasized
that the prescribing of BCV and TVR must be undertaken by
professionals with knowledge and experience of HCV, including
20ECDC. Annual epidemiological report on communicable
diseases in Europe 2009. [cited 2015 Sept] Available from:
http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_
Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf
TABLE 5 | Description 4E method—Education, Engineering, Economics, and Enforcement (Garuoliene et al., 2010; Godman et al., 2010a,b, 2014b, 2015;
Maticic, 2014; Moon et al., 2014; Putrik et al., 2014; Campbell et al., 2015).
Approach Description and examples
Education • Activities include educational programmes that influence prescribing: e.g., national and regional guidelines with inclusion criteria, monitoring
requirements, EBM initiatives (rational prescribing), and benchmarking (quality control), e.g., monitoring of prescribing against agreed guidance
coupled with feedback, e.g., “Wise list” in Stockholm, Sweden
• Activities also include education for patients including public awareness through campaigns, world hepatitis day, flyers/printed material, as well as
prescribing guidance for patients to enhance patient-doctor communication
Engineering • This refers to organizational or managerial interventions
• Activities include programs and interventions to optimize prescribing: e.g., structured programmes to optimize the entry of new medicines, price:
volume agreements, capping budgets, and prescribing targets
• In addition any disease management programmes to optimize treatment including potential quality targets
Economics • Activities include positive and negative financial initiatives for all key stakeholder groups
• Examples include percentage reimbursement/patient co-payment levels as well as financial incentives for physicians
Enforcement • Activities include regulations such as those enforced by law; e.g., prescribing restrictions including designated signatures on prescription forms, prior
authorization schemes and compulsory agreements such as compulsory international non-proprietary name (INN) prescribing and compulsory generic
substitution
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testing and treatment1,2. Consequently, triple therapy must be
prescribed by doctors who specialize in HCV management1,2.
This is typically the case for BCV and TVR, which are only
licensed for GT1. This means physicians are obliged to test for
genotypes before starting treatment.
All European countries that reimbursed triple therapy
typically had no patient co-payment. We are aware that risk
sharing agreements and discounts are used by health authorities
to control budgets, enabling patients to have access to new
high priced medicines (Adamski et al., 2010; Ferrario and
Kanavos, 2013). However, data on the extent of any discounts
are typically lacking as such arrangements are confidential. As
a result, we were unable to document any cost/DDD data for
BCV and TVR in Scotland (Tayside). Reimbursement for HIV
co-infection and treatment before and after liver transplantation
currently exists in a number of European countries including
Austria, Ireland, Catalonia, Scotland, Slovakia, Slovenia
and Sweden.
Utilization
The uptake of BCV and TVR varied between the countries
and over time (Figures 1A,B). The highest uptake for TVR
was in Tayside (Scotland) in the second quarter of 2012 at
2.4 DIQs. The highest uptake of BCV was in Belgium at 1.32
DIQs. Subsequently all countries showed a decrease of HCV
medicines between approximately 6 months after triple therapy
reimbursement, e.g., the Netherlands, Belgium, and Slovenia,
and 12 months after triple therapy reimbursement, e.g., Austria,
Denmark, Catalonia and Sweden. Utilization of BCV was highest
in Belgium with 38% in third quarter after reimbursement (Q1
2013) and lowest in Italy and Estonia.
The upper and lower range (dotted lines in Figures 2, 3)
illustrate the utilization of BCV and TVR if all potential patients
with GT1 prevalence of 45–65% were treated (see comments in
Table 4). For TVR, only Sweden meets the upper limit, which
equates to the 65% GT1 prevalence and greatest percentage
of therapy containing TVR. Only Austria, Estonia, Italy, and
Catalonia do not meet the lower limit, indicating that even in
a hypothetical situation with low GT1 prevalence and a short
DAA treatment length, not all patients who should receive triple
therapy actually receive it. For BCV, Belgium touches the lower
limit with lowest GT1 prevalence and a lowest percentage of
treatment containing BCV. Due to lack of patient specific data,
prevalence data and different algorithms, the utilization of BCV
and TVR are not consolidated. However, after adding BCV and
TVR together, Belgium, Denmark, the Netherlands and Sweden
appear to have the highest uptake of triple therapy vs. dual
therapy.
Expenditure Data
Table 7 contains reimbursed expenditure/DDD data for both
BCV and TVR up to May 2013. Turkey was excluded as only
IMS data were available. Estonia was excluded as these medicines
have only recently been reimbursed, and Scotland (Tayside) was
excluded as reimbursed data included confidential discounts;
consequently unavailable for analysis. There were no differences
in the documented prices between medicines dispensed in
hospital pharmacies for out-patients or community pharmacies.
However, this did not include any confidential discounts as part
of risk sharing or other agreements (Adamski et al., 2010; Ferrario
and Kanavos, 2013; Vogler et al., 2013).
For both BCV and TVR, Denmark appeared to pay the
highest reimbursed price at 131.52 and 384.53 EUR/DDD
respectively. Catalonia (Spain) appeared to pay the lowest
reimbursed price at 103.92 EUR/DDD for BCV and Slovenia
the lowest reimbursed price for TVR at 291.64 EUR/DDD.
Only Austria had a major price decrease from EUR 146.60 to
EUR 116.1 per DDD during the course of the study following
agreements.
Total expenditure for HCV treatments was decreasing
in all countries before the reimbursement of BCV and
TVR, especially in Catalonia and Austria (Figure 4),
and again prior to the availability of the newer second
generation DAAs, at the end of 2012 and beginning of
FIGURE 1 | Uptake BCV and TVR across European countries from the month first reimbursed. Each Bar represents a 3 month period. Only the first quarter
of 2012 and 2013 is displayed in the legend to include all countries. (A) Included countries are: AU, Austria; BE, Belgium; DK, Denmark; EE, Estonia; ES (CT),
Catalonia (Spain). (B) Included countries are: IT, Italy; NL, the Netherlands; UK-Scot (TS), Tayside (Scotland); SI, Slovenia; SE, Sweden; TR, Turkey.
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TABLE 6 | Summary of most important demand side measures among European countries to influence the prescribing of BCV and TVR post-launch.
Country 4E Approach
Austria Enforcement • Prior authorization scheme with cost-sharing for TVR
Engineering • PIs are reimbursed according to the published “limitations of prescription”—as long as a patient meets the criteria defined in the
“limitations of prescription” his/her treatment will be approved and thus reimbursed
• No reimbursement of BCV for null responders
Belgium Enforcement • Need prior approval from the Health Insurance companies according to agreed criteria (chapter IV medicine) before PIs can be used.
• Otherwise, 100% patient co-payment if prescribing does not follow agreed criteria
Bosnia and
Herzegovina
(Republic of
Srpska)
Education • Guidelines available for the diagnosis and treatment of chronic hepatitis C
• Increasing public awareness as well as campaigns stating that there is free, voluntarily, anonymous testing and counseling for
patients with suspected HCV. Alongside this, distribution of educational materials—helped by establishing counseling centers for
hepatitis and HIV
Economics • Therapy initiated only in specialist centers for patients with hepatitis
Engineering • Health Insurance Fund purchases medicines for patients with HCV under a 1-year (centralized tender) with defined reimbursement
conditions; otherwise 100% co-payment
Enforcement • However, neither BCV (market authorization in B&H in 2012) or TVR (no application so far submitted in B&H) are currently
reimbursed (100% co-payment); so far (March 2016) there have been no requests for a refund sent to the Health Insurance Fund
• Proposed wholesale price by the manufacturer within the market authorization process was €4720/package
Croatia Engineering
Enforcement
• Incidence and prevalence of HCV has been declining in Croatia in recent years through preventative measures. These include
ensuring safety of blood products, reducing drug abuse as well as programs to reduce infection rates among intravenous drug users
• Both BCV and TVR are reimbursed and on the list of expensive products since 2013 (BCV in Official Gazette 49/2013 and for TVR in
Official Gazette 67/2013)
• They are both reimbursed for triple therapy but with defined guidance for use for reimbursement. Treatment is reimbursed only in
hospitals to ensure prescribing is in line with current guidelines/guidance
France Education
Engineering
Enforcement
• The prevention and management of HCV has been on the public health agenda in France since the early 1990s, with an extensive
network of hepatologists and reference centers
• The authorities through the referral centers also research outcomes from current treatment approaches
• Only physicians specialized in hepatology, internal medicine or infectious diseases are allowed to initiate treatment with DAAs
including BCV and TVR
Iceland Education • Both BCV and TVR are reimbursed
• Guidelines are available but currently no health authority activities directing prescribing
• More recently a nationwide treatment-project where all HCV infected patients are being offered the second generation DDA’s over a
2–3 years period.
• Alongside this, a large scale epidemiological study is ongoing to ascertain whether it is possible eliminate HCV from a small,
relatively confined population such as Iceland
Ireland Education
Engineering
Economics
Enforcement
• Surveillance system in place to collect effectiveness, safety, tolerability and economic outcomes from current treatments including
BCV and TVR
• All patients prescribed triple therapy are obliged to be registered with the Irish Hepatitis C Outcome and Research Network (ICORN)
treatment database which captures longitudinal data
• Dispensing of BCV and TPR is restricted to hospitals only to ensure appropriate governance of treatment
Italy Education
Engineering
Economics
Enforcement
• Italian Horizon Scanning group issuing information on medicines for patients with chronic HCV to national and regional authorities
• Price volume agreements - if expenditure on BCV and TVR exceeds pre-set thresholds, manufacturers payback any differences to
the Italian National Health Service
• As a result, BCV has a patient cap of 6000 patients for 2 years and a sales cap of €120 million/year and 5% discount with pegIFN.
TVR has a patient cap of 2000 patients the first year, 3000 patients for the second year and re-negotiation above 4000 patients.
Sales cap of €100 million/per year. Re-negotiation above €80 million per year21
• Physicians need to be validated by the Italian Medicines Agency with only selected centers and physicians allowed to prescribe
treatment.
• In the Veneto Region, a special network of centers exists to administer HCV medicines
(Continued)
21Cicchetti A. La tensión regulación- innovación en las decisiones de precio y re-embolso de nuevos medicamentos en Italia. [cited 2015 Jan] Available from:
http://www.fgcasal.org/fgcasal/database/documentos/PharmaMar-FGC_2012_AMERICO_CICCHETTI-2.pdf
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TABLE 6 | Continued
Country 4E Approach
• Patient registers are in place for patients receiving PI to monitor their use according to agreed guidance (and increasingly monitor
outcomes in the future). Patient entry encouraged as part of the payment system for hospitals; otherwise hospitals will not
reimbursed for the medicines costs for patients with HCV
Malta Economics,
Enforcement
• Treatments initially were not reimbursed by the National Health Service. Some patients bought their treatment privately or were
supported through NGOs. Alpha interferon was originally used and later pegylated interferon and ribavirin became standard
treatments in Malta (Brincat et al., 2013)
• Subsequently, a one-time donation of medicines was undertaken by pharmaceutical companies enabling some patients to be
initiated with ledipasvir/sofosbuvir
• Recently, newer treatments including sofosbuvir were included in the National Formulary List to be provided free of charge through
the National Health Service. Their use is regulated by protocols approved by the HCV Patient Management Committee
Netherlands Enforcement • Need prior approval according to agreed guidance before a PI can be dispended
Slovakia Enforcement • To be eligible for reimbursement, a psychiatrist must make a statement that drug abusers are abstinent for at least 1 year
Slovenia Education
Engineering
Enforcement
• Detailed patient register schemes which include additional data for prescribing a PI: fibrosis stage, IL28B type, prior HCV treatment,
type of PI included in treatment, lead-in phase and rapid virological response
• When patients with HCV are treated, data is added according to the national protocol for the management of HCV in patients with
HCV. The registry was established in 2007
• Slovenia has a National Viral Hepatitis Expert Group since 1997, established to develop national treatment guidelines and evaluate
the efficacy and safety of different treatment approaches in clinical practice
• Since 1997, there is a national network of a named list of infectologists and hepatologists in 5 reference centers for treatment of viral
hepatitis. These are the only physicians who can prescribe HCV therapy (in accordance with the national guidelines)
• Since 2007, there is an interdisciplinary National healthcare network across the country for the treatment of HCV in patients who
inject themselves with drugs
• The Health Insurance Institute of Slovenia (ZZZS) has a possibility to control physician prescribing where regulations exist. When
prescribing is not in line with prescribing restrictions, the provider physician/hospital has to pay a fine
Spain—
Catalonia
Education
Engineering
Economics
• Available algorithms of chronic HCV treatment at a national and regional level, including IL28B testing as well as selection of dual or
triple therapy in naïve/relapsers/non-responder patients
• Register of prevalence and treatment outcomes ongoing
• Data from surveillance systems are used to regularly monitor expenditure and benchmarking among hospitals. Also monitoring of
erythropoiesis factor requirements (management and impact of side effects)
• PI related data incorporated into the surveillance system. This includes the numbers of patients treated for HCV treated with a PI,
which PI and PegIFN is selected as well as co-infected patients with HIV and organ transplanted patients treated with a PI
• It is recommended a multidisciplinary treatment approach is undertaken to improve care including for instance a
gastroenterologist/infectious disease physician, psychiatrist, pharmacist and laboratory testing personnel
• Annual budgets for outpatient drug treatments are allocated to Catalan public hospitals (including drugs for cancer, HCV, multiple
sclerosis, etc.) to help control costs
• There are currently no patient co-payments for HCV medicines in Catalan public hospitals
Sweden Education
Engineering
Economics
• National treatment guidelines available to guide treatment
• BCV is currently not reimbursed by the TLV (Dental and Pharmaceutical Benefits Agency - reimbursement authority in Sweden) but
TVR is. However, all drugs for HCV infection, including TVR and BCV, are free for the patient since medicines for infectious diseases
including Hepatitis C are free under the Infectious Diseases Act
• TVR is currently reimbursed without restriction
Turkey
(Aygen et al.,
2015)
Engineering
Enforcement
• BCV and TVR are reimbursed with restricted indications, e.g., triple therapy is reimbursed in combination with TVR in patients
infected with HCV genotype 1 who have compensated liver disease and who have previously received PegIFN/RBV therapy and
relapsed
• In patients with compensated liver disease, total treatment duration is 48 weeks with 12 weeks of TVR therapy, provided that the
liver biopsy Ishak score is stage ≥4, the platelet count is below 100,000/mm3, or the prothrombin time is over 3 seconds
• In relapsed patients, total treatment duration is 24 weeks, including 12 weeks of TVR therapy if HCV RNA is negative at week 4 of
treatment, and 48 weeks if HCV RNA is positive at week 4 of treatment
UK—
Scotland
Engineering • Pro-active approach to the introduction of triple therapy including BCV and TCR
• Patient numbers are tracked to check they agree with original predictions and the case for funding (in Tayside)
NB. BCV, Boceprevir; DAAs, direct acting antivirals; pegIFN, pegylated interferon; PI, Protease inhibitor; TVR, Telaprevir. Estonia is not included in the Table as the pharmaceutical
companies were providing first generations DAAs free of charge until recently.
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FIGURE 2 | Percentage utilization of TVR vs. ribavirin in quarters following reimbursement. NB: Upper range genotype 1 prevalence (=GT1) is 65% and
highest percentages (50%) triple therapy containing TVR (mostly non-cirrhotic patients). Lower range GT1 prevalence is only 45% and lowest percentages (25%) triple
therapy containing TVR (mostly cirrhotic patients).
FIGURE 3 | Percentage utilization of BCV vs. ribavirin in quarters following reimbursement. Upper range genotype 1 prevalence (=GT1) is 65% and highest
percentages (92%) triple therapy containing BVC (mostly cirrhotic patients). Lower range GT1 prevalence is only 45% and lowest percentages (67%) triple therapy
containing BVC (mostly naïve non-cirrhotic patients).
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FIGURE 4 | Expenditure on treatments for HCV (Euro/1000 inhabitants/quarter) from 2008 to 2013. NB:©=reimbursement agreed BVC. Sweden and
Denmark first quarter after EMA approval are included.
TABLE 7 | Reimbursed Euro per DDD (EUR/DDD) from the time of
reimbursement until the latest available data (May 2013) of TVR and BCV.
Telaprevir (TVR) Boceprevir (BCV)
EUR/DDD EUR/DDD EUR/DDD EUR/DDD
when reimbursed 05-2013 when reimbursed 05-2013
Austria* 321.48 310.44 146.60 116.11
Belgium* 324.58 324.54 116.66 116.66
Belgium** 315.29 – 113.31 –
Croatia**/*** 331.97 331.97 123.46 123.46
Denmark** 394.65 384.53 145.53 131.62
Netherlands* 300.23 302.66 114.51 114.05
Slovenia* 302.31 291.64 113.10 113.10
Spain-Catalonia** 304.74 304.74 103.92 103.92
Sweden* 329.49 294.82 117.69 118.52
NB: *Dispensed in community pharmacy; **Dispensed in hospital pharmacy; ***Price from
basic list and price from expensive product list (same prices). Reimbursed prices of BCV
and TVR should not be compared as different treatment paradigms.
2013. Denmark and Slovenia had the lowest increase in
EUR/1000 inhabitants/3 months after the reimbursement of
BCV and TVR. This was 99 and 89% respectively between
the lowest and highest EUR/1000 inhabitants/3 months
from just before impending reimbursement of these two
medicines to just after. This compares with a rise of 385% in
Catalonia.
DISCUSSION
Our analysis showed reasonable consistency in the uptake of
BCV and TVR among the European countries studied (Figure 1)
compared with appreciable differences that have been seen in
the utilization of new high priced medicines to treat patients
with rheumatoid arthritis, type 2 diabetes and cancer across
Europe (Hoebert et al., 2012; Jönsson et al., 2014; Putrik
et al., 2014; Nolte and Corbett). This is despite appreciable
differences among the participating countries in their level of
spending on healthcare as well as the percentage of GDP they
spend on health (Table 1). This might be explained firstly by
the fact that all European countries followed EMA labeled
indications with strict regulations for clear genotyping and
SVR monitoring. Secondly, there were relatively few measures
implemented among European health authorities to influence
physician prescribing of either BCV or TVR apart from directing
prescribing to specialists and specialist centers and entering
patients into registries. Thirdly, both treatments were typically
100% reimbursed although there are exceptions (Table 6).
The rapid uptake of BCV and TVR across countries (Figure 1)
may be explained by expectancy among professionals and
patients regarding the increased efficacy of these first generation
DAAs vs. previous regimens. This resulted in countries placing
patients on waiting lists to receive triple therapy soon after
BCV and TVR were reimbursed. Whilst we cannot say this
with certainty, this is in line with decreasing costs of ribavirin
and pegIFNs before reimbursement of the new PIs (Figure 4).
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Additionally, European guidelines advised postponing HCV
treatment until the new DAAs including sofosbuvir became
available in view of their greater efficacy and tolerability as well as
reduced length of treatment (European Association for the Study
of the Liver, 2011; Hatzakis et al., 2011).
The consistency in the utilization of BCV and TVR across
Europe appears promising, especially considering a desire to
reduce infection rates whilst attempting to keep the budgets for
these medicines manageable. Any differences in utilization rates
of BCV and TVR between countries (Figure 1) could potentially
be explained by differences in HCV and GT1 prevalence
variations as well as local physician preferences and knowledge
rather than any specific health authority interventions (Table 6).
However, we cannot comment further as we did not have access
to patient level data. In addition, we did not explore key issues
among specialist physicians involved in the management of
patients with HCV.
Reimbursed prices for BCV and TVR (EUR/DDD) also
appeared comparable among the European countries studied.
This did not include risk-sharing agreements including rebates
and discounts as information about these agreements is limited,
with the exception of Italy. This is because such measures are
typically confidential.
The upper and lower ranges identified in Figures 2, 3 suggest
that the uptake of triple therapy appears reasonable in a
number of the studied countries based on the assumptions of
GT1 prevalence and treatment algorithms (Table 4); although,
lower in some countries. However, there needs to be caution
when interpreting these results as a number of assumptions
were made (Table 4), and we are aware of the concerns with
current estimated prevalence rates for HCV GT1 (Table 1).
Utilization data can also be complicated by other factors, which
include patients being selected for dual therapy if they have a
low HCV RNA viral load after 4 weeks or ILB28B favorable
CC polymorphism. Analysis of subsequently available patient
level data in Stockholm, Sweden, showed that among patients
initiated on treatment in 2012, total (TVR+BCV)/ribavirin was
approximately 64% in 2012, which corresponds to Figures 2,
3 (Frisk, Personal Communication). However, in Catalonia,
TVR+BCV/ribavirin was used in approximately 18.6% of
patients, which is higher than in our study (Ibáñez, Personal
Communication). In a recent report involving Italy, France,
Germany, Spain and UK, most gastroenterologists stated that
triple therapy would be prescribed more for non-responders
in the first year of its availability. By 2014, 60% of treatment-
naïve patients were expected to be treated with triple therapy22.
This wide predicted variation in the prescribing of DAAs was
not seen in practice (Figures 1A,B), with the utilization of
BCV and TVR (Figures 1A,B) appearing more similar compared
with the appreciable differences in the utilization of other
high priced medicines, e.g., TNF alpha inhibitors and those
to treat patients with cancer or Type 2 diabetes (Hoebert
22HCV new drug research. Hepatitis C News; European Gastroenterologists
Will Prescribe Telaprevir and Boceprevir to Nonresponder and Treatment-
Naive Patients Following Launch [Internet]. 2011 Available from: http://
hepatitiscnewdrugs.blogspot.dk/2011/04/hepatitis-c-news-european.html
(Accessed 10 Oct 2015).
et al., 2012; Jönsson et al., 2014; Putrik et al., 2014; Nolte and
Corbett).
One reason for the lower than expected surge in the use
of triple therapy in Europe could be that efficacy and safety
data from clinical trials are not always replicated in clinical
practice and side effects can be more frequent and severe. This
is especially the case in treatment-experienced HCV patients as
observed in the French cohort reported by Hézode et al. (2013,
2014). The same phenomenon has been seen in Ireland where
the effectiveness in patients entered into the registry (Table 6)
was considerably lower than those seen from the clinical trials
(O’Leary, Personal Communication). Published studies in the
US have shown that the uptake of triple therapy was also
relatively low, although TVR (INCIVEK R©) reached 1 US$ billion
within a short time and US$1.6 billion after the first year23.
In a small study (487 GT1 patients), only 18.7% of patients
received triple therapy in the first year after FDA approval (Chen
et al., 2013). Reasons not to start triple therapy were principally
contraindications (50%). Of all the patients who started triple
therapy, 21% discontinued it. This was mostly because of side
effects (Chen et al., 2013). Other studies have also concluded
that side effects are the most frequent barrier for chronic HCV
treatment (McGowan et al., 2013).
Consequently, side effects and complexity of drug treatment
posology of PIs may explain the decrease in utilization and
expenditure of BCV and TVR in recent years among European
countries (Figures 1, 4) coupled with the anticipation of the new
second generation DAAs, with less side effects, shorter treatment
durations, the potential for interferon free regimens and the
potential for cures (Brennan and Shrank, 2014; Kohli et al.,
2014)3. We are aware for instance that in Catalonia, France and
Sweden, a number of potentially eligible patients for BCV and
TVR were put on waiting lists until the launch of the second
generation DAAs, and probably in other countries as well.
This observation is strengthened by recent findings showing
that sofosbuvir, after TVR, was the fastest growing prescribed
medicine in the US with sales of US$2.27 billion in the first
quarter of 201424 reaching, as mentioned, US$12.4 billion
worldwide in 2014. This accounted for 37.5% of expenditure
on HCV medicines among managed care organizations in 2014
(Trooskin et al., 2015)11. This expenditure is helped by the cost
of a standard 12-week course of sofosbuvir and simeprevir being
initially at US$84 000 and US$66,000 in the US respectively,
with sofosbuvir initially priced at between Euro 50,000 and
60,000 per 12-week course among Eurozone countries, although
U$54,000 (€44,000) in the UK and€41,000 in France (Brennan
and Shrank, 2014; Lemoine and Asia, 2014; Phelan and Cook,
2014; van de Ven et al., 2014; Trooskin et al., 2015; Iyengar
et al., 2016). These prices, coupled with the prevalence of
HCV, have already resulted in activities among countries to
23Incivek set to break record for fastest product launch [Internet].
EvaluatePharma. [cited 2015 Nov]. Available from: http://epvantage.com/
Universal/View.aspx?type=Story&id=261529&isEPVantage=yes
24Gilead Sciences Announces First Quarter 2014 Financial Results [Internet].
Gilead Sciences Inc. 2014. [cited 2015 Nov] Available from: http://www.gilead.
com/news/press-releases/2014/4/gilead-sciences-announces-first-quarter-2014-
financial-results [Internet] (Accessed 8 July 2016).
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control costs through price negotiations and other strategies.
This is not surprising with potential sales of US$15 trillion if
an estimated 180 million people worldwide with HCV were
treated with sofosbuvir (Montazerhodjat et al., 2016). Table 8
summarizes some of the activities, exacerbated for instance by
the authorities in France initially being charged sofosbuvir at 756
times the cost of its production in France (Phelan and Cook,
2014).
There are also ongoing activities among other African
countries including Botswana and Zimbabwe given the
higher prevalence of HCV in developing countries and
the potential for generic agreements. These differences in
policies for the second generation DAAs is already leading
to considerable differences in their utilization rates in
Europe34.
Recent analysis has shown there is still appreciable variation in
the price of second generation DAAs across countries (Andrieux-
Meyer et al., 2015). For instance, the price per bottle of sofosbuvir
(28 tablets) ranges from $300 (India and Pakistan) and $402
(Nigeria—current market survey) to $20,590 in Switzerland, and
for daclatasvir from $175 in Egypt and $252 in Nigeria (current
market survey) to $14,899 in Germany (Andrieux-Meyer et al.,
2015). Overall, prices are generally substantially lower in LMIC
countries although there are outliers, with little correlation
between prices and per capita income levels among higher
income countries, e.g., the price for a bottle of simeprevir ranges
from U$9166 in Spain to US$14,865 in Australia (Andrieux-
Meyer et al., 2015).
It is likely that prices of second generation DAAs will continue
falling across countries with estimates of manufacturing for
12-week courses at US$10-$30 for daclatasvir, US$68–$136 for
sofosbuvir, US$100–$210 for faldaprevir and US$130–$270 for
simeprevir (Hill et al., 2014) coupled with increased competition.
This should also help the management of patients with genotypes
4, 5, and 6 that are mainly present in Africa, the Middle East
and Asia, where resources are more limited (Papastergiou and
Karatapanis, 2015). Their availability as oral therapies coupled
with the potential of avoiding genotyping with its associated
facilities and costs should further help with increased usage and
price negotiations (Ford et al., 2014; Younossi et al., 2015).
Prices should also fall further following the inclusion of
sofosbuvir, simeprevir dasabuvir and daclatasvir in the 19th
edition of the WHO Model List of Essential Medicines along
with comments to negotiate affordable prices35. This alongside
the formation of consortia, which is already happening in
the US with State Medicaid schemes, following the example
of ARVs where prices reduced substantially following strong
pressure from multiple stakeholders (Lemoine and Asia, 2014).
In addition, the potential development of a Global Fund for
treatments for patients with HCV or other mechanisms (Phelan
and Cook, 2014).
34CNAMTS. Ameliorér la qualité du système de sante et maîtriser les depenses.
Propositions de l’Assuarance Maladie pour 2016. [Internet]. Available from:
http://www.ameli.fr/rapport-charges-et-produits-2016/ (Accessed Feb 2016).
35World Health Organization “19th WHO Model List of Essential Medicines
(April 2015)”. Geneva. Available at URL: http://www.who.int/medicines/
publications/essentialmedicines/EML2015_8-May-15.pdf (Accessed Oct 2015).
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The undoubted effectiveness of the second generation DAAs
is making European and other health authorities re-think their
approaches to valuing new high priced medicines. This includes
new medicines for patients with cancer, as well as those for
orphan diseases, which are being reimbursed at high prices
despite often very limited health gain in view of patient pressure
and other factors (Fojo and Grady, 2009; Hughes-Wilson et al.,
2012; Experts in Chronic Myeloid Leukemia, 2013; Kantarjian
et al., 2013; Simoens et al., 2013; Cohen and Felix, 2014;
Ghinea et al.). This will continue and be the subject of future
research projects among the co-authors. Future research will
also include assessing the utilization and expenditure on second
generation DAAs in clinical practice among European countries
as they become standards of care (Childs-Kean and Hand, 2015),
building on early analysis by the French authorities and others33.
CONCLUSION
There appears to be reasonable consistency in the uptake and
utilization of BCV and TVR among the studied European
countries in comparison with other new high priced medicines.
This may reflect the high social impact of chronic HCV
treatment, especially with few health authority measures
implemented to influence physician prescribing. However, using
ribavirin as a benchmark hints at differences in the utilization
of BCV and TVR. This may indicate that the prescribing of
dual vs. triple therapy differs across countries. This cannot be
explained by looking at health authority activities for these
two treatments and may just reflect physician preference.
Consequently, more information including GT1 prevalence data
and data on treatment algorithms (including treatment length
and treatment period containing PI) is needed to explain this.
There are also ongoing activities with the second generation
DAAs across countries to reduce their costs in view of
their undoubted effectiveness and tolerability alongside their
considerable budget impact. This will be the subject of future
research to provide additional guidance to authorities in the face
of continuing resource pressures.
AUTHOR CONTRIBUTIONS
WdB, CI, PF, HBP, and BG contributed to the design of the
paper and the methodology. They also produced the first and
subsequent drafts. AA, PVB, AB, LB, GD, JE, JOF, JF, GG, IG,
AG, HG, SJ, JJ, RJ, SK, OL, NM, EM,MM, VM-P, AM, OO, AO’L,
JP, CS, SS, CT, IT, MT, KT, MW, SV, EV, and CZ provided data
on the utilization of BCV and TVR and/or ongoing measures
within their own countries to improve the prevention and/or
management of HCV. They also critiqued successive drafts of the
paper. All authors read and approved the final manuscript.
ACKNOWLEDGMENTS
We acknowledge the help of Paolo Siviero, ex AIFA in Italy, for
his help with providing data and information from Italy. We
wish to thank Theresa Bucsics, Department of Gastroenterology
and Hepatology, Medical University of Vienna, for her helpful
comments. This work was in part supported by grants from
the World Health Organization and the Karolinska Institutet,
Sweden. The write-up was in part supported by a Newton
Advanced Fellowship awarded to Professor Augusto Afonso
Guerra Junior by the Academy of Medical Sciences, through
the UK Government’s Newton Fund programme. It was also
in part supported by a VR-Link grant from Swedish Research
Council (VR-Link 2013-6710) to AM. GG has been supported
by the Swedish Research Council Carl Wilhelm Scheeles Guest
Professorship.
REFERENCES
Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osiñska, B., Herholz,
H., Wendykowska, K., et al. (2010). Risk sharing arrangements for
pharmaceuticals: potential considerations and recommendations for European
payers. BMC Health Serv. Res. 10:153. doi: 10.1186/1472-6963-10-153
Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., and Hamid, S. S. (2015). Disparity
in market prices for hepatitis C virus direct-acting drugs. Lancet Glob. Heal. 3,
e676–e677. doi: 10.1016/S2214-109X(15)00156-4
Atun, R., Aydın, S., Chakraborty, S., Sümer, S., Aran, M., Gürol, I., et al. (2013).
Universal health coverage in Turkey: enhancement of equity. Lancet 382,
65–99. doi: 10.1016/S0140-6736(13)61051-X
Aygen, B., Yıldız, O., Akhan, S., Çelen, M. K., Ural, O., Koruk, S.
T., et al. (2015). Retreatment of Chronic Hepatitis C Infection with
Telaprevir: preliminary results in Turkey. Balkan. Med. J. 32, 266–272. doi:
10.5152/balkanmedj.2015.15366
Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., and Taylor, L. E. (2015).
Restrictions for medicaid reimbursement of sofosbuvir for the treatment of
hepatitis C virus infection in the United States. Ann. Int. Med. 163, 215–223.
doi: 10.7326/M15-0406
Björkhem-Bergman, L., Andersén-Karlsson, E., Laing, R., Diogene, E., Melien,
O., Jirlow, M., et al. (2013). Interface management of pharmacotherapy. Joint
hospital and primary care drug recommendations. Eur. J. Clin. Pharmacol.
69(Suppl. 1), 73–78. doi: 10.1007/s00228-013-1497-5
Brennan, T., and Shrank, W. (2014). New expensive treatments for hepatitis C
infection. JAMA 312, 593–594. doi: 10.1001/jama.2014.8897
Brincat, A. A., Deguara, M., Taliana, K., Rogers, M., and Pocock, J. (2013). The
management of patients positive to hepatitis C virus antibody in Malta. Malta
Med. J. 25, 72–77.
Cacace, M., Ettelt, S., Mays, N., and Nolte, E. (2013). Assessing quality
in cross-country comparisons of health systems and policies: towards
a set of generic quality criteria. Health Policy 112, 156–162. doi:
10.1016/j.healthpol.2013.03.020
Campbell, S. M., Godman, B., Diogene, E., Fürst, J., Gustafsson, L. L., MacBride-
Stewart, S., et al. (2015). Quality indicators as a tool in improving the
introduction of new medicines. Basic. Clin. Pharmacol. Toxicol. 116, 146–157.
doi: 10.1111/bcpt.12295
Canary, L., Klevens, R., and Holmberg, S. (2015). Limited access to new hepatitis C
virus treatment under state medicaid programs. Ann. Int. Med. 163, 226–228.
doi: 10.7326/M15-0320
Cebolla, B., and Björnberg, A. (2012). Euro Hepatitis Index
Report - Health Consumer Powerhouse. Available online at:
http://www.healthpowerhouse.com/files/euro-hepatitis-index-2012/Report-
Hepl-HCP-121104-2-w-Cover.pdf
Chen, E. Y., Sclair, S. N., Czul, F., Apica, B., Dubin, P., Martin, P., et al. (2013).
A small percentage of patients with hepatitis C receive triple therapy with
boceprevir or telaprevir.Clin. Gastroenterol. Hepatol. 11, 1014–1020.e1–e2. doi:
10.1016/j.cgh.2013.03.032
Frontiers in Pharmacology | www.frontiersin.org 15 July 2016 | Volume 7 | Article 197
de Bruijn et al. HCV Medicines
Childs-Kean, L. M., and Hand, E. O. (2015). Simeprevir and sofosbuvir for
treatment of Chronic Hepatitis C Infection. Clin. Ther. 37, 243–267. doi:
10.1016/j.clinthera.2014.12.012
Chou, R., Hartung, D., Rahman, B., Wasson, N., and Cottrell, E. B. (2014).
Comparative effectiveness of antiviral treatment for Hepatitis C Virus infection
in adults: a systematic review. Ann. Int. Med. 158, 114–123. doi: 10.7326/0003-
4819-158-2-201301150-00576
Christensen, P. B., Clausen, M. R., Krarup, H., Laursen, A. L., Schlichting, P.,
and Weis, N. (2012). Treatment for hepatitis B virus (HBV) and hepatitis C
virus (HCV) infection - Danish national guidelines 2011. Dan. Med. J. 59,
C4465.
Civaner, M. (2012). Sale strategies of pharmaceutical companies in a
“pharmerging” country: the problems will not improve if the gaps remain.
Health Policy 106, 225–232. doi: 10.1016/j.healthpol.2012.05.006
Cohen, J. P., and Felix, A. (2014). Are payers treating orphan drugs differently? J.
Mark. Access Health Policy 2, 1–5. doi: 10.3402/jmahp.v2.23513
Coma, A., Zara, C., Godman, B., Agustí, A., Diogène, E., Wettermark, B., et al.
(2009). Policies to enhance the efficiency of prescribing in the Spanish Catalan
region: impact and future direction. Expert Rev. Pharmacoecon Outcomes Res.
9, 569–81. doi: 10.1586/erp.09.58
Cornberg, M., Razavi, H. A., Alberti, A., Bernasconi, E., Buti, M., Cooper,
C., et al. (2011). A systematic review of hepatitis C virus epidemiology in
Europe, Canada and Israel. Liver Int. 31(Suppl. 2), 30–60. doi: 10.1111/j.1478-
3231.2011.02539.x
Cure, S., Guerra, I., Cammà, C., Craxì, A., and Carosi, G. (2015). Cost-effectiveness
of sofosbuvir plus ribavirin with or without pegylated interferon for the
treatment of chronic hepatitis C in Italy. J. Med. Econ. 18, 678–690. doi:
10.3111/13696998.2015.1040024
Deuffic-Burban, S., Deltenre, P., Buti, M., Stroffolini, T., Parkes, J., Mühlberger,
N., et al. (2012). Predicted effects of treatment for HCV infection
vary among European countries. Gastroenterology 143, 974–985.e14. doi:
10.1053/j.gastro.2012.05.054
Dore, G. J., Ward, J., and Thursz, M. (2014). Hepatitis C disease burden and
strategies to manage the burden. J. Viral Hepat. 21(Suppl. 1), 1–4. doi:
10.1111/jvh.12253
European Association for the Study of the Liver (2011). EASL clinical practice
guidelines: management of Hepatitis C virus infection. J. Hepatol. 55, 245–264.
doi: 10.1016/j.jhep.2011.02.023
European Association for the Study of the Liver (2014). EASL clinical practice
guidelines: management of Hepatitis C Virus infection. J. Hepatol. 60, 392–420.
doi: 10.1016/j.jhep.2013.11.003
European Centre for Desease Prevention and Control (2010). Hepatitis B and C in
the EU Neighbourhood: Prevalence. Burden: Burden of Disease and Screening
Policies.
Experts in Chronic Myeloid Leukemia (2013). The price of drugs for chronic
myeloid leukemia (CML) is a re fl ection of the unsustainable prices of cancer
drugs: from the perspective of a large group of CML experts. Blood 121,
4439–4442. doi: 10.1182/blood-2013-03-490003
Ferrario, A., and Kanavos, P. (2013). Managed Entry Agreements for
Pharmaceuticals: The European Experience. LSE. Available onlinje at: http://
eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario%2C%20A_
Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_
%20entry_%20agreements_2013.pdf (Accessed on: 15 Oct 2015).
Fojo, T., and Grady, C. (2009). How much is life worth: cetuximab, non-small cell
lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 101, 1044–1048.
doi: 10.1093/jnci/djp177
Ford, N., Swan, T., Beyer, P., Hirnschall, G., Easterbrook, P., andWiktor, S. (2014).
Simplification of antiviral hepatitis C virus therapy to support expanded access
in resource-limited settings. J. Hepatol. 61(Suppl. 1). S132–S138. doi: 10.1016/j.
jhep.2014.09.019
Fraser, I., Burger, J., Lubbe, M., Dranitsaris, G., Sonderup, M., and Stander,
T. (2016). Cost-effectiveness modelling of sofosbuvir-containing regimens
for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Pharmacoeconomics 34, 403–417. doi: 10.1007/s40273-015-0356-x
Garuoliene, K., Alonderis, T., and Marcinkevic, M. (2010). Pharmaceutical policy
and the effects of the economic crisis: Lithuania. Eurohealth 17, 1–4.
Garuoliene, K., Godman, B., Gulbinoviè, J., Wettermark, B., and Haycox, A.
(2011). European countries with small populations can obtain low prices for
drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 11,
343–349. doi: 10.1586/erp.11.24
Ghinea, N., Kerridge, I., and Lipworth, W. If we don’t Talk About Value, Cancer
Drugs Will Become Terminal for Health Systems [Internet]. Available online at:
http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-
become-terminal-for-health-systems-44072 (Accessed on Oct 2015).
Godman, B., Bishop, I., Finlayson, A. E., Campbell, S., Kwon, H.-Y., and
Bennie, M. (2013b). Reforms and initiatives in Scotland in recent years to
encourage the prescribing of generic drugs, their influence and implications
for other countries. Expert Rev Pharmacoecon Outcomes Res. 13, 469–482. doi:
10.1586/14737167.2013.820956
Godman, B., De Bruyn, K., Miranda, J., Raschi, E., Bennie, M., and
Barbui, C. (2013a). Generic atypical antipsychotic drugs in Belgium: their
influence and implications. J. Comp. Eff. Res. 2, 551–561. doi: 10.2217/
cer.13.75
Godman, B., Malmström, R. E., Diogene, E., Gray, A., Jayathissa, S., and Timoney,
A. (2015). Are new models needed to optimise the utilisation of new medicines
to sustain healthcare systems? Expert Rev. Clin. Pharmacol. 8, 77–94. doi:
10.1586/17512433.2015.990380
Godman, B., Malmström, R. E., Diogene, E., Jayathissa, S., McTaggart, S., Cars, T.,
et al. (2014b). Dabigatran - a continuing exemplar case history demonstrating
the need for comprehensive models to optimize the utilization of new drugs.
Front. Pharmacol. 5:109. doi: 10.3389/fphar.2014.00109
Godman, B., Petzold, M., Bennett, K., Bennie, M., Bucsics, A., Finlayson, A. E.,
et al. (2014a). Can authorities appreciably enhance the prescribing of oral
generic risperidone to conserve resources? Findings from across Europe and
their implications. BMCMed. 12:98. doi: 10.1186/1741-7015-12-98
Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T.,
et al. (2010a). Policies to enhance prescribing efficiency in europe: findings
and future implications. Front. Pharmacol. 1:141. doi: 10.3389/fphar.2010.
00141
Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T.,
et al. (2010b). Comparing policies to enhance prescribing efficiency in Europe
through increasing generic utilization: changes seen and global implications.
Expert Rev. Pharmacoecon. Outcomes Res. 10, 707–722. doi: 10.1586/
erp.10.72
Gower, E., Estes, C. C., Hindman, S., Razavi-Shearer, K., and Razavi, H. (2014).
Global epidemiology and genotype distribution of the hepatitis C virus.
J. Hepatol. 61, S45–S57. doi: 10.1016/j.jhep.2014.07.027
Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., et al. (2011).
The state of hepatitis B and C in Europe: report from the hepatitis B and C
summit conference. J. Viral Hepat. 18(Suppl. 1), 1–16. doi: 10.1111/j.1365-2893.
2011.01499.x
Hesse, U., Godman, B., Petzold, M., Martin, A., andMalmström, R. (2013). Impact
of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark:
implications for other countries. Appl. Heal Econ. Heal Policy 11, 677–685. doi:
10.1007/s40258-013-0059-4
Hézode, C., Fontaine, H., Dorival, C., Larrey, D., Zoulim, F., Canva, V.,
et al. (2013). Triple therapy in treatment-experienced patients with HCV-
cirrhosis in a multicentre cohort of the French Early Access Programme
(ANRS CO20-CUPIC) - NCT01514890. J. Hepatol. 59, 434–441. doi:
10.1016/j.jhep.2013.04.035
Hézode, C., Fontaine, H., Dorival, C., Zoulim, F., Larrey, D., Canva, V., et al.
(2014). Effectiveness of telaprevir or boceprevir in treatment-experienced
patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147,
132–142.e4. doi: 10.1053/j.gastro.2014.03.051
Hill, A., Khoo, S., Fortunak, J., Simmons, B., and Ford, N. (2014). Minimum
costs for producing hepatitis C direct-acting antivirals for use in large-scale
treatment access programs in developing countries. Clin. Infect. Dis. 58,
928–936. doi: 10.1093/cid/ciu012
Hoebert, J. M., Mantel-Teeuwisse, A. K., van Dijk, L., Bijlsma, J. W. J., and
Leufkens, H. G. M. (2012). Do rheumatoid arthritis patients have equal
access to treatment with new medicines? Tumour necrosis factor-alpha
inhibitors use in four European countries. Health Policy 104, 76–83. doi:
10.1016/j.healthpol.2011.10.011
Hofmann, W. P., Sarrazin, C., and Zeuzem, S. (2012). Current standards in the
treatment of chronic hepatitis C.Dtsch. Arztebl. Int. 109, 352–358. doi: 10.3238/
arztebl.2012.0352
Frontiers in Pharmacology | www.frontiersin.org 16 July 2016 | Volume 7 | Article 197
de Bruijn et al. HCV Medicines
Hope, V. D., Eramova, I., Capurro, D., and Donoghoe, M. C. (2014). Prevalence
and estimation of hepatitis B and C infections in the WHO European Region:
a review of data focusing on the countries outside the European Union and
the European Free Trade Association. Epidemiol. Infect. 142, 270–286. doi:
10.1017/S0950268813000940
Hughes-Wilson, W., Palma, A., Schuurman, A., and Simoens, S. (2012). Paying for
the Orphan Drug System: break or bend? Is it time for a new evaluation system
for payers in Europe to take account of new rare disease treatments? Orphanet.
J. Rare Dis. 7:74. doi: 10.1186/1750-1172-7-74
Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K.,
et al. (2016). Prices, costs, and affordability of new medicines for Hepatitis
C in 30 countries: an economic analysis. PLoS med. 13:e1002032. doi:
10.1371/journal.pmed.1002032
Jönsson, B., Ramsey, S., and Wilking, N. (2014). Cost effectiveness in practice
and its effect on clinical outcomes. J. Cancer Policy 2, 12–21. doi:
10.1016/j.jcpo.2014.02.001
Kantarjian, H. M., Fojo, T., Mathisen, M., and Zwelling, L. A. (2013). Cancer
drugs in the United States: Justum Pretium–the just price. J. Clin. Oncol. 31,
3600–3604. doi: 10.1200/JCO.2013.49.1845
Kohli, A., Shaffer, A., Sherman, A., and Kottilil, S. (2014). Treatment of Hepatitis
C. JAMA. 312, 631. doi: 10.1001/jama.2014.7085
Lagging, M., Duberg, A.-S., Wejstål, R., Weiland, O., Lindh, M., Aleman, S., et al.
(2012). Treatment of hepatitis C virus infection in adults and children: updated
Swedish consensus recommendations. Scand. J. Infect. Dis. 44, 502–521. doi:
10.3109/00365548.2012.669045
Lemoine, M., and Asia, E. (2014). Hepatitis C, A Global Issue: access to care
and new therapeutic and preventive approaches in resource-constrained areas.
Semin. Liver Dis. 34, 89–97 doi: 10.1055/s-0034-1371082
Leroy, V., Serfaty, L., Bourlière, M., Bronowicki, J.-P., Delasalle, P., Pariente, A.,
et al. (2012). Protease inhibitor-based triple therapy in chronic hepatitis C:
guidelines by the French Association for the Study of the Liver. Liver Int. 32,
1477–14492. doi: 10.1111/j.1478-3231.2012.02856.x
Lo Re, V. III., Teal, V., Localio, A., Amorosa, V., Kaplan, D., and Gross, R. (2011).
Relationship between adherence to hepatitis C virus therapy and virologic
outcomes: a cohort study. Annals of internal medicine. Ann. Intern. Med. 155,
353–360. doi: 10.7326/0003-4819-155-6-201109200-00003
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al.
(2012). Global and regional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 380, 2095–2128. doi: 10.1016/S0140-6736(12)61728-0
Malmström, R. E., Godman, B. B., Diogene, E., Baumgärtel, C., Bennie, M.,
Bishop, I., et al. (2013). Dabigatran - a case history demonstrating the need for
comprehensive approaches to optimize the use of new drugs. Front. Pharmacol.
4:39. doi: 10.3389/fphar.2013.00039
Manns, M. P., Pockros, P. J., Norkrans, G., Smith, C. I., Morgan, T. R., Häussinger,
D., et al. (2013). Long-term clearance of hepatitis C virus following interferon
α-2b or peginterferon α-2b, alone or in combination with ribavirin. J. Viral
Hepat. 20, 524–529. doi: 10.1111/jvh.12074
Manzano-Robleda, M. C., Ornelas-arroyo, V., Barrientos-gutiérrez, T., Méndez-
sánchez, N., Uribe, M., and Chávez-tapia, N. C. (2015). Boceprevir and
telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic
review and meta-analysis. Ann. Hepatol. 14, 46–57.
Mathurin, P. (2013). HCV burden in Europe and the possible impact of current
treatment. Dig. Liver Dis. 45, S314–S317. doi: 10.1016/j.dld.2013.07.009
Maticic, M. (2014). A national multidisciplinary healthcare network for treatment
of hepatitis C in people who inject drugs in Slovenia. BMC Infect Dis. 14(Suppl
6):S6. doi: 10.1186/1471-2334-14-S6-S6
McGowan, C. E., Monis, A., Bacon, B. R., Mallolas, J., Goncales, F. L., Goulis, I.,
et al. (2013). A global view of hepatitis C: physician knowledge, opinions, and
perceived barriers to care. Hepatology 57, 1325–1332. doi: 10.1002/hep.26246
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C.,
et al. (2002). Adherence to combination therapy enhances sustained response
in genotype-1–infected patients with chronic hepatitis C. Gastroenterology 123,
1061–1069. doi: 10.1053/gast.2002.35950
McHutchison, J., Stuart, C., Schiff, E., Shiffman, M., Lee, W., and Rustgi,
V. (1998). Interferon alfa-2b alone or in combination with ribavirin as
initial treatment for chronic hepatitis C. NEJM 339, 1485–1492. doi:
10.1056/NEJM199811193392101
Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G.,
et al. (2014). Global distribution and prevalence of hepatitis C virus genotypes.
Hepatology 61, 77–87. doi: 10.1002/hep.27259
Messori, A. (2015a). Newest treatments for hepatitis C: how can we manage
sustainability? Clin. Infect. Dis. 16, 1891–1892. doi: 10.1093/cid/civ667
Messori, A. (2015b). Value-based pricing is inadequate for both high budget-
impact drugs and orphan drugs: exploring original methods to overcome this
limitation by adjusting prices according to the number of potential patients.
BMJ 351:h4988.
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., and Wiersma, S. T. (2013).
Global epidemiology of hepatitis C virus infection: new estimates of age-
specific antibody to HCV seroprevalence. Hepatology 57, 1333–1342. doi:
10.1002/hep.26141
Montazerhodjat, V., Weinstock, D. M., and Lo, A. W. (2016). Buying cures versus
renting health: financing health care with consumer loans. Sci. Transl. Med. 8,
327ps6. doi: 10.1126/scitranslmed.aad6913
Moon, J. C., Godman, B., Petzold, M., Alvarez-Madrazo, S., Bennett, K., Bishop,
I., et al. (2014). Different initiatives across Europe to enhance losartan
utilization post generics: impact and implications. Front. Pharmacol. 5:219. doi:
10.3389/fphar.2014.00219
Nolte, E., and Corbett, J. International Variation in Drug Usage Variation: An
Exploratory Analaysis of the “Causes” of Variation [Internet]. [cited 2015Mar 8].
Available online at: http://www.rand.org/pubs/research_reports/RR899.html
Norton, A. (2015). Hepatitis C Drugs Will ‘Strain Budgets’ at Current Prices:
Study - The New Therapies Have Remarkably High Cure Rates. Available online
at: URL: http://consumer.healthday.com/infectious-disease-information-21/
hepatitis-news-373/hepatitis-c-drugs-will-strain-budgets-at-current-prices-
study-697479.html
Orlent, H., Deltenre, P., Francque, S., Laleman,W., Moreno, C., Bourgeois, S., et al.
(2012). Update of the Belgian Association for the Study of the Liver guidelines
for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
Acta Gastroenterol. Belg. 75, 245–259.
Papastergiou, V., and Karatapanis, S. (2015). Current status and emerging
challenges in the treatment of hepatitis C virus genotypes 4 to 6.World J. Clin.
Cases. 3, 210–220. doi: 10.12998/wjcc.v3.i3.210
Phelan, M., and Cook, C. (2014). A treatment revolution for those who can afford
it? Hepatitis C treatment: new medications, profits and patients. BMC Infect
Dis. 14(Suppl 6):S5. doi: 10.1186/1471-2334-14-S6-S5
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., et al.
(1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for
24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of
chronic infection with hepatitis C virus. International Hepatitis Interventional
Therapy Group (IHIT). Lancet 352, 1426–1432.
Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., et al. (2014).
Inequities in access to biologic and synthetic DMARDs across 46 European
countries. Ann. Rheum. Dis. 73, 198–206. doi: 10.1136/annrheumdis-2012-
202603
Ramachandran, P., Fraser, A., Agarwal, K., Austin, A., Brown, A., Foster, G. R.,
et al. (2012). UK consensus guidelines for the use of the protease inhibitors
boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Aliment. Pharmacol. Ther. 35, 647–662. doi: 10.1111/j.1365-2036.2012.04992.x
Rein, D. (2015). Reply to Messori. Clin. Infect. Dis. 61, 1892–1893. doi:
10.1093/cid/civ668
Schalm, S.W., Hansen, B. E., Chemello, L., Bellobuono, A., Brouwer, J. T.,Weiland,
O., et al. (1997). Meta-analysis of individual patient data from European
centers. J. Hepatol. 26, 961–966. doi: 10.1016/S0168-8278(97)80103-1
Senior, M. (2014). Sovaldi makes blockbuster history, ignites drug pricing unrest.
Nat. Biotechnol. 32, 501–502. doi: 10.1038/nbt0614-501
Simoens, S., Picavet, E., Dooms, M., Cassiman, D., and Morel, T. (2013). Cost-
effectiveness assessment of orphan drugs: a scientific and political conundrum.
Appl. Health Econ. Health Policy. 11, 1–3. doi: 10.1007/s40258-012-0004-y
Thein, H.-H., Yi., Q., Dore, G. J., and Krahn, M. D. (2008). Estimation of stage-
specific fibrosis progression rates in chronic hepatitis C virus infection: a
meta-analysis and meta-regression. Hepatology 48, 418–431. doi: 10.1002/hep.
22375
Trooskin, S. B., Reynolds, H., and Kostman, J. R. (2015). Access to costly new
hepatitis C drugs: medicine, money, and advocacy. Clin. Infect. Dis. 61,
1825–1830. doi: 10.1093/cid/civ677
Frontiers in Pharmacology | www.frontiersin.org 17 July 2016 | Volume 7 | Article 197
de Bruijn et al. HCV Medicines
van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S., et al.
(2014). Minimum target prices for production of direct-acting antivirals and
associated diagnostics to combat Hepatitis C Virus. Hepatology 61, 1174–1182.
doi: 10.1002/hep.27641
Vogler, S., Zimmermann, N., Habl, C., and Mazag, J. (2013). The role of discounts
and loss leaders in medicine procurement in Austrian hospitals - a primary
survey of official and actual medicine prices. Cost Effect. Resour. Alloc. 11:15.
doi: 10.1186/1478-7547-11-15
Vonèina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S.,
et al. (2011). Influence of demand-side measures to enhance renin-angiotensin
prescribing efficiency in Europe: implications for the future. Expert Rev.
Pharmacoecon. Outcomes Res. 11, 469–479. doi: 10.1586/erp.11.42
Wedemeyer, H., Dore, G. J., and Ward, J. W. (2015). Estimates on HCV disease
burden worldwide - filling the gaps. J. Viral Hepat. 22(Suppl. 1), 1–5. doi:
10.1111/jvh.12371
Westbrook, R. H., and Dusheiko, G. (2014). Natural history of hepatitis C.
J. Hepatol. 61(1 Suppl.), S58–S68. doi: 10.1016/j.jhep.2014.07.012
Wettermark, B., Godman, B., Jacobsson, B., and Haaijer-Ruskamp, F. M. (2009).
Soft regulations in pharmaceutical policy making: an overview of current
approaches and their consequences. Appl. Health Econ. Health Policy 7,
137–147. doi: 10.1007/BF03256147
World Health Organisation (2012). The 10 Leading Causes of Death by Country
Income Group. Available onlie at: http://www.who.int/mediacentre/factsheets/
fs310/en/index1.html.
Yehia, B. R., Schranz, A. J., Umscheid, C. A., and Lo Re, V. (2014). The
treatment cascade for chronic hepatitis C virus infection in the United
States: a systematic review and meta-analysis. PLoS ONE 9:e101554. doi:
10.1371/journal.pone.0101554
Younossi, Z. M., Park, H., Saab, S., Ahmed, A., Dieterich, D., and Gordon, S. C.
(2015). Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients
with chronic hepatitis C virus genotype 1 infection. Aliment. Pharmacol. Ther.
41, 544–563. doi: 10.1111/apt.13081
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 de Bruijn, Ibáñez, Frisk, Bak Pedersen, Alkan, Vella Bonanno,
Brkicˇic´, Bucsics, Dedet, Eriksen, Fadare, Fürst, Gallego, Godói, Guerra Júnior,
Gürsöz, Jan, Jones, Joppi, Kerman, Laius, Madzikwa, Magnússon, Maticic,
Markovic-Pekovic, Massele, Ogunleye, O’Leary, Piessnegger, Sermet, Simoens,
Tiroyakgosi, Truter, Thyberg, Tomekova, Wladysiuk, Vandoros, Vural, Zara and
Godman. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 18 July 2016 | Volume 7 | Article 197
